Laura Lozza
Icahn School of Medicine at Mount Sinai
CancerInternal medicineRadiologySurgeryOncologyDermatologyRetrospective cohort studyRandomized controlled trialSurvival rateChemotherapyBreast surgerySarcomaBreast-conserving surgerySkin erythemaToxicityNuclear medicineIn patientRadiation therapyBreast cancerMedicineCumulative incidence
94Publications
18H-index
2,486Citations
Publications 91
Newest
#1Nicola RoccoH-Index: 13
#1Nicola RoccoH-Index: 4
Last. Maurizio B. NavaH-Index: 22
view all 20 authors...
Abstract Introduction The potential advantages of oncoplastic breast conserving surgery (BCS) have not been validated in robust studies that constitute high levels of evidence, despite oncoplastic techniques being widely adopted around the globe. There is hence the need to define the precise role of oncoplastic BCS in the treatment of early breast cancer, with consensual recommendations for clinical practice. Methods A panel of world-renowned breast specialists was convened to evaluate evidence,...
Source
BACKGROUND AND PURPOSE Randomized trials confirmed the efficacy and the safety of hypofractionated whole breast irradiation (HF-WBI) in patients with early-stage breast cancer. However, the role of HF-WBI in patients with DCIS after breast conserving surgery has not yet been clearly established in prospective randomized trials. The aim of this study was to evaluate if HF-WBI can be considered comparable to conventionally fractionated (CF)-WBI in DCIS patients. MATERIALS AND METHODS The analysis ...
Source
#2Chiara ListortiH-Index: 1
Last. Secondo FolliH-Index: 17
view all 10 authors...
Abstract Introduction Although the need for axillary lymph node dissection (AD) is decreasing in breast cancer patients, it remains necessary in some cases. Axillary reverse mapping (ARM) enables the detection of upper extremity lymphatic drainage that may be spared during selective axillary dissection (SAD) so as to reduce the risk of lymphedema. The ability of the ARM-SAD procedure to reduce the incidence of lymphedema is being tested in an ongoing randomized trial. Crossover between arm drain...
1 CitationsSource
#1Tim Rattay (University of Leicester)H-Index: 9
#2Petra Seibold (DKFZ: German Cancer Research Center)H-Index: 27
Last. Sheryl GreenH-Index: 18
view all 119 authors...
Background: Acute skin toxicity is a common and usually transient side-effect of breast radiotherapy although, if sufficiently severe, it can affect breast cosmesis, aftercare costs and the patient's quality-of-life. The aim of this study was to develop predictive models for acute skin toxicity using published risk factors and externally validate the models in patients recruited into the prospective multi-center REQUITE (validating pREdictive models and biomarkers of radiotherapy toxicity to red...
1 CitationsSource
#1Rossana IngargiolaH-Index: 3
#2Maria De SantisH-Index: 35
Last. Ester OrlandiH-Index: 22
view all 22 authors...
This study was an open-label, 2-arms, monocentric, randomized clinical trial comparing Xonrid®, a topical medical device, versus standard of care (SOC) in preventing and treating acute radiation dermatitis (ARD) in Head and Neck Cancer (HNC) and Breast Cancer (BC) patients undergoing radiotherapy (RT). Eligible HNC and BC patients were randomized 1:1 to receive Xonrid® + SOC or SOC during RT. Patients were instructed to apply Xonrid® on the irradiated area three times daily, starting on the firs...
Source
#1Angelo Vitullo (University of Milan)H-Index: 1
#2Maria De SantisH-Index: 35
Last. Laura LozzaH-Index: 1
view all 5 authors...
2 CitationsSource
#1E. La Rocca (University of Milan)H-Index: 1
Last. Maria De SantisH-Index: 35
view all 13 authors...
AIM: To assess the impact of age, comorbidities and endocrine therapy (ET) in older breast cancer (BC) patients treated with hypofractionated radiotherapy (Hypo-RT). METHODS: From June 2009 to December 2017, we enrolled in this study 735 ER-positive BC patients (stage pT1-T2, pNx-1, M0 and age ≥ 65 years) receiving hypo-RT and followed them until September 2019. Baseline comorbidities included in the hypertension-augmented Charlson Comorbidity Index were retrospectively retrieved. Logistic regre...
1 CitationsSource
#1E. La RoccaH-Index: 1
#2Laura LozzaH-Index: 18
Last. M. De SantisH-Index: 15
view all 11 authors...
To report acute toxicities in breast cancer (BC) patients (pts) recruited in a prospective trial and treated with accelerated partial-breast irradiation (APBI) using Volumetric Modulated Arc Therapy (VMAT) delivered with a hypofractionated schedule. From March 2014 to June 2019, pts with early-stage BC (Stage I), who underwent breast conservative surgery (BCS), were recruited in a prospective study started at the National Cancer Institute of Milan. Pts received APBI with a hypofractionated sched...
Source
Last. Secondo FolliH-Index: 17
view all 11 authors...
Background:Ductal carcinoma in situ (DCIS) is considered a morphologic precursor of invasive cancer and is often treated with adjuvant whole-breast irradiation and endocrine therapy, as if it were ...
Source
#1Eliana La Rocca (University of Milan)H-Index: 2
Last. Maria De SantisH-Index: 35
view all 13 authors...
: To assess the efficacy, and the acute and late toxicity of hypofractionated radiotherapy (Hypo-RT), and the impact of age and comorbidities on disease progression and death in elderly breast cancer (BC) patients. Women aged ≥65 years who received Hypo-RT (42.4 Gy in 16 fractions, plus a boost for high-risk patients) were considered for the present analysis. Competing risk analysis was used to estimate the 5-year cumulative incidence of BC progression and BC-related death, calculating the adjus...
2 CitationsSource